Brief: Curevac Announces Solid Progress In Phase 2 Covid-19 And Seasonal Flu Clinical Development Programs In Collaboration With Gsk
01/11/2023 12:06
Nov 1 (Reuters) - CureVac NV 5CV.DE :
* CUREVAC ANNOUNCES SOLID PROGRESS IN PHASE 2 COVID-19 AND
SEASONAL FLU CLINICAL DEVELOPMENT PROGRAMS IN COLLABORATION WITH
GSK
* CUREVAC- COVID-19 PHASE 2 CLINICAL TRIAL FULLY ENROLLED
Source text for Eikon: ID:
Further company coverage: 5CV.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028